Immunohistochemical differentiation of reactive from malignant mesothelium as a diagnostic aid in canine pericardial disease
Open Access
- 2 April 2018
- journal article
- research article
- Published by Wiley in Journal of Small Animal Practice
- Vol. 59 (5) , 261-271
Abstract
Objectives: To develop a provisional immunohistochemistry panel for distinguishing reactive pericardium, atypical mesothelial proliferation and mesothelioma in dogs.Materials and Methods: Archived pericardial biopsies were subject to haematoxylin and eosin staining, immunohistochemistry for cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Samples were scored for intensity and number of cells stained.Results: Ten biopsies of reactive mesothelium, 17 of atypical mesothelial proliferation, 26 of mesothelioma and five of normal pericardium were identified on the basis of haematoxylin and eosin staining. Cytokeratin and vimentin were expressed in all biopsies, confirming mesothelial origin. Normal pericardial samples had the lowest scores for insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Mesothelioma and atypical proliferative samples were similar to each other, with higher scores for insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 than the reactive samples. Desmin staining was variable. Insulin‐like growth factor II mRNA‐binding protein 3 was the best to distinguish between disease groups.Clinical Significance: An immunohistochemistry panel of cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 could provide superior information compared with haematoxylin and eosin staining alone in the diagnosis of cases of mesothelial proliferation in canine pericardium, but further validation is warranted.Keywords
Funding Information
- PetSavers (02.14)
This publication has 35 references indexed in Scilit:
- IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial ProliferationsAmerican Journal of Surgical Pathology, 2013
- Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial ProliferationAmerican Journal of Surgical Pathology, 2011
- Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparationsDiagnostic Cytopathology, 2011
- Echocardiographic and clinicopathologic characterization of pericardial effusion in dogs: 107 cases (1985–2006)Journal of the American Veterinary Medical Association, 2009
- Immunocytochemical differentiation of canine mesenchymal tumors in cytologic imprint preparationsVeterinary Clinical Pathology, 2008
- Feline diabetes mellitus in the UK: The prevalence within an insured cat population and a questionnaire-based putative risk factor analysisJournal of Feline Medicine and Surgery, 2007
- Biochemical Analysis of Pericardial Fluid and Whole Blood in Dogs with Pericardial EffusionJournal of Veterinary Internal Medicine, 2005
- Immunohistochemical characterization of the lesions of canine idiopathic pericarditisJournal of Small Animal Practice, 2002
- Embolization of mesothelial cells in lymphatics: the route to mesothelial inclusions in lymph nodes?Histopathology, 1998
- Mesothelioma in pet dogs associated with exposure of their owners to asbestosEnvironmental Research, 1983